Erlotinib (Tarceva): Potent HER1/epidermal growth factor receptor inhibition: Introduction

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalSeminars in Oncology
Volume30
Issue number3 SUPPL. 7
StatePublished - Jun 1 2003

Fingerprint

Epidermal Growth Factor Receptor
Erlotinib Hydrochloride

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Erlotinib (Tarceva) : Potent HER1/epidermal growth factor receptor inhibition: Introduction. / Arteaga, Carlos L.

In: Seminars in Oncology, Vol. 30, No. 3 SUPPL. 7, 01.06.2003, p. 1-2.

Research output: Contribution to journalArticle

@article{ea5aac2a28bb4d369e278a8fc5827085,
title = "Erlotinib (Tarceva): Potent HER1/epidermal growth factor receptor inhibition: Introduction",
author = "Arteaga, {Carlos L.}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "30",
pages = "1--2",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 7",

}

TY - JOUR

T1 - Erlotinib (Tarceva)

T2 - Potent HER1/epidermal growth factor receptor inhibition: Introduction

AU - Arteaga, Carlos L.

PY - 2003/6/1

Y1 - 2003/6/1

UR - http://www.scopus.com/inward/record.url?scp=0038343129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038343129&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0038343129

VL - 30

SP - 1

EP - 2

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 7

ER -